JPH1179948A - Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion - Google Patents
Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretionInfo
- Publication number
- JPH1179948A JPH1179948A JP9267818A JP26781897A JPH1179948A JP H1179948 A JPH1179948 A JP H1179948A JP 9267818 A JP9267818 A JP 9267818A JP 26781897 A JP26781897 A JP 26781897A JP H1179948 A JPH1179948 A JP H1179948A
- Authority
- JP
- Japan
- Prior art keywords
- represented
- chemical formula
- hair
- cis
- mentha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001256 tonic effect Effects 0.000 title claims abstract description 7
- 239000002537 cosmetic Substances 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 12
- 210000002374 sebum Anatomy 0.000 title claims description 11
- 230000028327 secretion Effects 0.000 title claims description 11
- XMLSXPIVAXONDL-PLNGDYQASA-N Jasmone Chemical compound CC\C=C/CC1=C(C)CCC1=O XMLSXPIVAXONDL-PLNGDYQASA-N 0.000 claims abstract description 21
- 239000001296 salvia officinalis l. Substances 0.000 claims abstract description 20
- 240000002657 Thymus vulgaris Species 0.000 claims abstract description 14
- 235000007303 Thymus vulgaris Nutrition 0.000 claims abstract description 14
- 244000042664 Matricaria chamomilla Species 0.000 claims abstract description 13
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims abstract description 13
- 244000025221 Humulus lupulus Species 0.000 claims abstract description 12
- 235000008694 Humulus lupulus Nutrition 0.000 claims abstract description 12
- -1 methyl dihydroisojasmonate Chemical compound 0.000 claims abstract description 12
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 9
- 244000178231 Rosmarinus officinalis Species 0.000 claims abstract description 9
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 9
- 235000002912 Salvia officinalis Nutrition 0.000 claims abstract description 8
- YCIXWYOBMVNGTB-UHFFFAOYSA-N 3-methyl-2-pentylcyclopent-2-en-1-one Chemical compound CCCCCC1=C(C)CCC1=O YCIXWYOBMVNGTB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 240000007707 Mentha arvensis Species 0.000 claims abstract description 6
- 235000018978 Mentha arvensis Nutrition 0.000 claims abstract description 6
- 241000086254 Arnica montana Species 0.000 claims abstract description 5
- 241001479543 Mentha x piperita Species 0.000 claims abstract description 5
- 239000001771 mentha piperita Substances 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims description 17
- 241000218228 Humulus Species 0.000 claims description 12
- 235000002020 sage Nutrition 0.000 claims description 12
- 241000208983 Arnica Species 0.000 claims description 11
- 239000001585 thymus vulgaris Substances 0.000 claims description 11
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 7
- 241000546188 Hypericum Species 0.000 claims description 7
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 7
- 235000014435 Mentha Nutrition 0.000 claims description 7
- 241001072983 Mentha Species 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- IPWBXORAIBJDDQ-UHFFFAOYSA-N methyl 2-hexyl-3-oxocyclopentane-1-carboxylate Chemical compound CCCCCCC1C(C(=O)OC)CCC1=O IPWBXORAIBJDDQ-UHFFFAOYSA-N 0.000 claims description 4
- 235000017945 Matricaria Nutrition 0.000 claims description 2
- 241000009298 Trigla lyra Species 0.000 claims 3
- 241000894007 species Species 0.000 claims 2
- 239000000284 extract Substances 0.000 abstract description 23
- KVWWIYGFBYDJQC-UHFFFAOYSA-N methyl dihydrojasmonate Chemical compound CCCCCC1C(CC(=O)OC)CCC1=O KVWWIYGFBYDJQC-UHFFFAOYSA-N 0.000 abstract description 16
- 201000004384 Alopecia Diseases 0.000 abstract description 11
- 150000003505 terpenes Chemical class 0.000 abstract description 11
- 235000007586 terpenes Nutrition 0.000 abstract description 11
- 239000000419 plant extract Substances 0.000 abstract description 7
- 208000017520 skin disease Diseases 0.000 abstract description 3
- XMLSXPIVAXONDL-UHFFFAOYSA-N trans-jasmone Natural products CCC=CCC1=C(C)CCC1=O XMLSXPIVAXONDL-UHFFFAOYSA-N 0.000 abstract description 3
- 241000782597 Hypericum erectum Species 0.000 abstract description 2
- 231100000360 alopecia Toxicity 0.000 abstract description 2
- IVLCENBZDYVJPA-ARJAWSKDSA-N cis-Jasmone Natural products C\C=C/CC1=C(C)CCC1=O IVLCENBZDYVJPA-ARJAWSKDSA-N 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 235000015639 rosmarinus officinalis Nutrition 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 69
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 20
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 230000002280 anti-androgenic effect Effects 0.000 description 10
- 239000000469 ethanolic extract Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- 206010068168 androgenetic alopecia Diseases 0.000 description 9
- 229960003604 testosterone Drugs 0.000 description 9
- 208000002874 Acne Vulgaris Diseases 0.000 description 8
- 208000001840 Dandruff Diseases 0.000 description 8
- 206010000496 acne Diseases 0.000 description 8
- 230000003779 hair growth Effects 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000000051 antiandrogen Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- 244000246386 Mentha pulegium Species 0.000 description 4
- 235000016257 Mentha pulegium Nutrition 0.000 description 4
- 241001529742 Rosmarinus Species 0.000 description 4
- 229960003473 androstanolone Drugs 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 4
- 235000001050 hortel pimenta Nutrition 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 3
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010039792 Seborrhoea Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010052899 Ingrown hair Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229960000978 cyproterone acetate Drugs 0.000 description 2
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- ZNJFBWYDHIGLCU-HWKXXFMVSA-N jasmonic acid Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-HWKXXFMVSA-N 0.000 description 2
- 239000003915 liquefied petroleum gas Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AXMPUTNPYVTBSL-JLZSVDHQSA-N (5r,8s,9s,10r,13s,14s)-10,13-dimethyl-1,2,3,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-4-one Chemical class O=C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 AXMPUTNPYVTBSL-JLZSVDHQSA-N 0.000 description 1
- DYVQFOVKDXUCFA-UHFFFAOYSA-N 1-chlorooctadecane N,N-dimethylmethanamine Chemical compound CN(C)C.CCCCCCCCCCCCCCCCCCCl DYVQFOVKDXUCFA-UHFFFAOYSA-N 0.000 description 1
- LTVDFSLWFKLJDQ-IEOSBIPESA-N 2-[(3r,7r,11r)-3-hydroxy-3,7,11,15-tetramethylhexadecyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LTVDFSLWFKLJDQ-IEOSBIPESA-N 0.000 description 1
- IYFXXIUALYIKQR-UHFFFAOYSA-N 3-(cyclohepten-1-yl)cyclohept-2-en-1-one Chemical class O=C1CCCCC(C=2CCCCCC=2)=C1 IYFXXIUALYIKQR-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000275031 Nica Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 235000017716 Poliomintha incana Nutrition 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- YFNONBGXNFCTMM-UHFFFAOYSA-N butoxybenzene Chemical class CCCCOC1=CC=CC=C1 YFNONBGXNFCTMM-UHFFFAOYSA-N 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 150000004788 tropolones Chemical class 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、抗アンドロゲン作
用の相乗的な向上により、男性型脱毛症の予防,改善効
果が相乗的に増強された養毛剤及び毛髪用化粧料、並び
に、皮脂分泌抑制効果が相乗的に増強され、尋常性ざ
瘡,脂漏等の治療,改善に非常に有効な皮膚外用剤に関
する。TECHNICAL FIELD The present invention relates to a hair restorer and a cosmetic for hair in which the effect of preventing and ameliorating male pattern baldness is synergistically enhanced by synergistically improving the anti-androgen action, and the effect of inhibiting sebum secretion. The present invention relates to an external preparation for skin which is synergistically enhanced and is very effective for treating and improving acne vulgaris, seborrhea and the like.
【0002】さらに詳しくは、セージ(Salvia officin
alis L.),ホップ(Humulus lupulus L.),ローズマ
リー(Rosmarinus officinalis L.),オトギリソウ(H
ypericum erectum Thunb.),ハッカ(Mentha arvensis
L. var. piperascens Malinv.),セイヨウハッカ(Me
ntha piperita L.),カミツレ(Matricaria chamomill
a L.),アルニカ(Arnica montana L.),タイム(Thy
mus vulgaris L.)の各抽出物より選択される1種又は
2種以上と、テルペン類であるシス-ジャスモン(cis-j
asmone),メチルジヒドロイソジャスモネイト(methyl
dihydroisojasmonate),メチルジヒドロジャスモネイ
ト(methyl dihydrojasmonate)及びジヒドロジャスモ
ン(dihydrojasmone)より選ばれる1種又は2種以上を
含有して成る、相乗的に効果の増強された養毛剤及び毛
髪用化粧料、並びに皮脂分泌抑制用皮膚外用剤に関す
る。[0002] More specifically, sage ( Salvia officin)
alis L.), hops ( Humulus lupulus L.), rosemary ( Rosmarinus officinalis L.), hypericum ( H.
ypericum erectum Thunb.), Mentha ( Mentha arvensis )
L. var. Piperascens Malinv.), Mentha ( Me )
ntha piperita L.), chamomile ( Matricaria chamomill )
a L.), Arnica ( Arnica montana L.), Thyme ( Thy
mus vulgaris L.), and one or more cis-jasmon (cis-j) terpenes.
asmone), methyldihydroisojasmonate (methyl
dihydroisojasmonate, methyl dihydrojasmonate and one or more selected from dihydrojasmone, a synergistically enhanced hair restorer and cosmetic for hair, and sebum The present invention relates to a skin external preparation for secretion suppression.
【0003】[0003]
【従来の技術】男性ホルモンであるテストステロンに依
存性の尋常性ざ瘡,脂漏といった皮膚疾患に対して、従
来より抗アンドロゲン作用を有する薬剤が用いられてき
た。かかる抗アンドロゲン剤としては、酢酸シプロテロ
ンが代表的なものとして挙げられる。この酢酸シプロテ
ロンは、活性型テストステロンであるジヒドロテストス
テロンの受容体への結合を競合的に阻害するといわれて
いる。2. Description of the Related Art Drugs having an antiandrogenic effect have been used for skin diseases such as acne vulgaris and seborrhea which are dependent on the male hormone testosterone. A typical example of such an anti-androgen is cyproterone acetate. This cyproterone acetate is said to competitively inhibit the binding of dihydrotestosterone, an active form of testosterone, to the receptor.
【0004】また、やはりテストステロン依存性の男性
型脱毛症の改善及び防止には、2,4-ジアミノ-6-ピペリ
ジノピリミジン-3-オキシド(ミノキシジル),セファ
ランチン,ビタミンE誘導体,塩化カルプロニウムとい
った血行促進作用を有するもの、アデノシン三リン酸,
ウロガストロン,バイカレイン,パンテテイン-S-スル
ホン酸,奇数鎖脂肪酸誘導体といった毛母細胞賦活作用
を有するものが主に用いられてきた。[0004] In addition, to improve and prevent testosterone-dependent androgenetic alopecia, 2,4-diamino-6-piperidinopyrimidine-3-oxide (minoxidil), cepharanthin, vitamin E derivatives, carpronium chloride, etc. Adenosine triphosphate, which has a blood circulation promoting action,
Those having hair matrix activation such as urogastron, baicalein, pantethein-S-sulfonic acid, and odd-chain fatty acid derivatives have been mainly used.
【0005】さらに、男性型脱毛症がテストステロン依
存性であることから、テストステロンを活性型のジヒド
ロテストステロンに変換する酵素であるテストステロン
5α-リダクターゼを阻害する物質の検討が主としてなさ
れてきた。かかる阻害剤としては、アンドロスタノン誘
導体,ビシクロヘプテノン誘導体,フェノキシブタン誘
導体,トコフェリルキノン,トロポロン誘導体,ユビキ
ノン等の他、シソ科植物,キク科植物をはじめ多くの植
物の抽出物が知られている。[0005] Furthermore, since male pattern baldness is testosterone-dependent, testosterone, an enzyme that converts testosterone to active dihydrotestosterone, is used.
Investigations have mainly been made on substances that inhibit 5α-reductase. Examples of such inhibitors include androstanone derivatives, bicycloheptenone derivatives, phenoxybutane derivatives, tocopherylquinone, tropolone derivatives, ubiquinone, etc., as well as extracts of many plants including Lamiaceae and Asteraceae. I have.
【0006】しかしながら、上記の抗アンドロゲン剤,
血行促進剤,毛母細胞賦活剤或いはテストステロン5α-
リダクターゼ阻害剤の多くは、副作用の発現が懸念され
たり、製剤基剤中での安定性が悪かったり、作用が不十
分であったりして、十分な抗アンドロゲン活性と安定性
及び安全性を充足するものは少なかった。また、植物を
基原とするものについては、一定の品質のものを得るの
が困難で、さらに製剤化に際し好ましくない色や臭いを
有するものも多かった。[0006] However, the above-mentioned antiandrogen,
Blood circulation promoter, hair matrix activator or testosterone 5α-
Many reductase inhibitors have sufficient antiandrogenic activity and sufficient stability and safety due to concerns about the occurrence of side effects, poor stability in the formulation base, or insufficient action. There was not much to do. In addition, it is difficult to obtain a plant-based product having a certain quality, and many of the products have an unfavorable color or odor at the time of formulation.
【0007】[0007]
【発明が解決しようとする課題】従って本発明において
は、高い抗アンドロゲン作用を有し、低濃度の配合でテ
ストステロン依存性の脱毛症及び皮膚疾患を有効に治
療,改善することができ、しかも安定性が良好で、副作
用がなく安全性にも優れる養毛剤及び毛髪用化粧料、並
びに皮脂分泌抑制用皮膚外用剤を提供することを目的と
した。Accordingly, the present invention has a high antiandrogenic effect, and can effectively treat and improve testosterone-dependent alopecia and skin diseases by using a low concentration of the compound, and is stable. An object of the present invention is to provide a hair nourishing agent and a cosmetic for hair having good properties, no side effects and excellent safety, and a skin external preparation for suppressing sebum secretion.
【0008】[0008]
【課題を解決するための手段】本発明者らは植物精油中
のテルペン類に着目し、ジャスミン精油中に含まれる4
種のテルペンが非常に優れた抗アンドロゲン作用を有す
ることを見い出し、特許出願を行った(特願平8−20
3045)。今回、これらの1種又は2種以上と、テス
トステロン5α-リダクターゼ阻害活性を有するセージ
(Salvia officinalis L.)等特定の植物の抽出物より
選択される1種又は2種以上とを併用したところ、予想
外の抗アンドロゲン作用の増強が得られることを見いだ
し、本発明を完成するに至った。Means for Solving the Problems The present inventors have focused on terpenes in plant essential oils and have studied the terpenes contained in jasmine essential oil.
We have found that certain terpenes have very good antiandrogenic activity and filed a patent application (Japanese Patent Application No. 8-20).
3045). This time, when one or more of these were used in combination with one or more selected from extracts of specific plants such as sage ( Salvia officinalis L.) having testosterone 5α-reductase inhibitory activity, The present inventors have found that an unexpected enhancement of antiandrogen action can be obtained, and have completed the present invention.
【0009】すなわち本発明においては、化学式(1)
で表されるシス-ジャスモン(cis-jasmone),化学式
(2)で表されるメチルジヒドロイソジャスモネイト
(methyldihydroisojasmonate),化学式(3)で表さ
れるメチルジヒドロジャスモネイト(methyl dihydroja
smonate)及び化学式(4)で表されるジヒドロジャス
モン(dihydrojasmone)より選ばれる1種又は2種以上
と、セージ(Salvia officinalis L.),ホップ(Humul
us lupulus L.),ローズマリー(Rosmarinus officina
lis L.),オトギリソウ(Hypericum erectum Thun
b.),ハッカ(Mentha arvensis L. var. piperascens
Malinv.),セイヨウハッカ(Mentha piperita L.),
カミツレ(Matricaria chamomilla L.),アルニカ(Ar
nica montana L.),タイム(Thymus vulgaris L.)の
各抽出物より選択される1種又は2種以上とを、養毛剤
や毛髪用化粧料又は皮膚外用剤基剤中に含有させる。That is, in the present invention, the chemical formula (1)
Cis-jasmone represented by the formula, methyldihydroisojasmonate represented by the chemical formula (2), methyldihydrojasmonate represented by the chemical formula (3)
smonate) and one or more selected from dihydrojasmone represented by the chemical formula (4), sage ( Salvia officinalis L.), hop ( Humul )
us lupulus L.), rosemary ( Rosmarinus officina)
lis L.), Hypericum erectum Thun
b.), mint ( Mentha arvensis L. var. piperascens
Malinv.), Mentha Piperita L.,
Chamomile ( Matricaria chamomilla L.), Arnica ( Ar
nica montana L.) and thyme ( Thymus vulgaris L.) are contained in a hair restorer, a hair cosmetic or a skin external preparation base.
【化1】Embedded image
【化2】Embedded image
【化3】Embedded image
【化4】Embedded image
【0010】[0010]
【作用】本発明においては、有効成分として用いるシス
-ジャスモン等の4種のテルペン、或いはセージ(Salvi
a officinalis L.)等の植物抽出物を各単独で養毛剤等
に含有させた場合に比べて、それぞれともにより低濃度
の配合で、はるかに高い男性型脱毛症の改善効果及び皮
脂分泌抑制効果が認められた。かかる男性型脱毛症の改
善効果及び皮脂分泌抑制効果の増強は、活性型アンドロ
ゲンであるジヒドロテストステロンの受容体に対する結
合の競合的阻害と、テストステロン5α-リダクターゼ阻
害によるテストステロンからジヒドロテストステロンへ
の変換抑制とを介し、抗アンドロゲン効果が相乗的に向
上したことによるものと考えられる。In the present invention, cis used as an active ingredient is used.
-4 types of terpenes such as jasmon or sage ( Salvi
a officinalis L.), etc., compared with the case where each of them is contained alone in a hair nourishing agent, etc., a much higher improvement effect of male pattern baldness and suppression of sebum secretion can be achieved with a lower concentration of each. Admitted. The effect of improving male pattern baldness and the effect of suppressing sebum secretion are competitive inhibition of the binding of the active androgen dihydrotestosterone to the receptor, and inhibition of the conversion of testosterone to dihydrotestosterone by inhibiting testosterone 5α-reductase. It is considered that the anti-androgen effect was synergistically improved through
【0011】[0011]
【発明の実施の形態】シス-ジャスモン等のテルペン類
はそのまま添加してもよいが、エタノール,プロピレン
グリコール,ジプロピレングリコール,グリセリン,1,
3-ブチレングリコール,スクワラン等の液体担体、流動
パラフィン等の半固形担体、ワセリン等の固形担体に溶
解又は分散させたり、マイクロカプセルやリポソームに
内包させたりして、養毛剤,毛髪用化粧料或いは皮膚外
用剤基剤に含有させることもできる。DESCRIPTION OF THE PREFERRED EMBODIMENTS Terpenes such as cis-jasmon may be added as they are, but ethanol, propylene glycol, dipropylene glycol, glycerin,
It is dissolved or dispersed in a liquid carrier such as 3-butylene glycol or squalane, a semi-solid carrier such as liquid paraffin, or a solid carrier such as petrolatum, or encapsulated in microcapsules or liposomes to prepare a hair restorer, hair cosmetic or skin It can also be contained in an external preparation base.
【0012】また、セージ(Salvia officinalis L.)
等の植物抽出物は、これら植物を抽出溶媒中に浸漬して
得る。抽出には、各植物の花,葉,茎等の各部分及び全
草を用いることができる。これら植物はそのまま抽出処
理してもよいが、抽出効率を上げるためには、細切,粉
砕等した後抽出するか、抽出溶媒中でホモジネートする
ことが好ましい。抽出溶媒としては極性溶媒が好まし
く、水の他、メタノール,エタノール,プロパノール,
イソプロパノール,ブタノール等の低級アルコール類、
プロピレングリコール,ジプロピレングリコール,1,3-
ブチレングリコール,グリセリン等の多価アルコール
類、エチルエーテル,プロピルエーテル等のエーテル
類、酢酸エチル,酢酸ブチル等のエステル類、アセト
ン,エチルメチルケトン等のケトン類などが好ましいも
のとして挙げられ、これらより1種又は2種以上を選択
して用いる。また、リン酸緩衝液や生理食塩水も良好に
用いることができる。テストステロン5α-リダクターゼ
阻害活性の点からは、エタノールによる抽出が特に好ま
しい。抽出温度としては5〜50℃程度、抽出時間とし
ては4時間〜1週間程度が適切である。[0012] Sage ( Salvia officinalis L.)
Such plant extracts are obtained by immersing these plants in an extraction solvent. For the extraction, each part such as a flower, a leaf, a stem and the like of each plant and the whole plant can be used. These plants may be subjected to an extraction treatment as it is, but in order to increase the extraction efficiency, it is preferable to extract after shredding, pulverizing or the like, or to homogenate in an extraction solvent. As the extraction solvent, a polar solvent is preferable. In addition to water, methanol, ethanol, propanol,
Lower alcohols such as isopropanol and butanol,
Propylene glycol, dipropylene glycol, 1,3-
Preferred are polyhydric alcohols such as butylene glycol and glycerin, ethers such as ethyl ether and propyl ether, esters such as ethyl acetate and butyl acetate, and ketones such as acetone and ethyl methyl ketone. One or two or more are selected and used. Further, a phosphate buffer or a physiological saline can also be used favorably. Extraction with ethanol is particularly preferred from the viewpoint of testosterone 5α-reductase inhibitory activity. An appropriate extraction temperature is about 5 to 50 ° C., and an appropriate extraction time is about 4 hours to 1 week.
【0013】上記の植物抽出物は、そのまま養毛剤等の
基剤に添加してもよいが、濃縮,乾固したものを水や極
性溶媒に再度溶解したり、脱色,脱臭,脱塩等の精製処
理を行った後に添加してもよい。また、濃縮,乾固した
後、或いは精製処理を行った後に、凍結乾燥して粉末状
として添加してもよい。The above-mentioned plant extract may be added to a base such as a hair tonic as it is, but the concentrated and dried one may be redissolved in water or a polar solvent, or subjected to purification such as decolorization, deodorization and desalination. It may be added after the treatment. Further, after concentration and drying, or after performing a purification treatment, it may be freeze-dried and added as a powder.
【0014】本発明はローション剤,乳剤,ゲル剤,ク
リーム,軟膏等の形態で、皮脂抑制用の皮膚外用剤とし
て提供することができる。また、ヘアーローション,ヘ
アートニック,ヘアーミルク,ヘアージェル,ヘアーク
リーム,ヘアーパック,ヘアートリートメント,ヘアー
シャンプー,ヘアーリンスといった形態の養毛剤及び毛
髪用化粧料としても提供できる。皮膚外用剤,養毛剤又
は毛髪用化粧料基剤への配合量としては、シス-ジャス
モン等のテルペン類については1.0×10-5重量%〜
0.1重量%程度、セージ(Salvia officinalis L.)
等の植物抽出物としては、各植物500gを抽出溶媒
1.0l中でホモジネートして得た抽出物として、0.
001〜20重量%程度が適切である。The present invention can be provided in the form of a lotion, emulsion, gel, cream, ointment or the like as an external preparation for skin for suppressing sebum. Further, it can be provided as a hair restorer and a hair cosmetic in the form of a hair lotion, a hair tonic, a hair milk, a hair gel, a hair cream, a hair pack, a hair treatment, a hair shampoo, and a hair rinse. The amount of the terpene, such as cis-jasmon, added to the external preparation for skin, the hair tonic or the cosmetic base for hair is 1.0 × 10 -5 % by weight or more.
0.1% by weight, sage ( Salvia officinalis L.)
As an extract obtained by homogenizing 500 g of each plant in 1.0 liter of an extraction solvent, 0.1 g of each plant extract is used.
About 001 to 20% by weight is appropriate.
【0015】なお、本発明に係る養毛剤,毛髪用化粧料
及び皮脂分泌抑制用皮膚外用剤には、本発明の特徴を損
なわない範囲で、油脂類,低級アルコール類,多価アル
コール類,界面活性剤,保湿剤,細胞賦活剤,殺菌剤,
防腐剤,紫外線吸収剤,香料等、通常化粧料や皮膚外用
剤において用いられる原料や添加剤を含有させることが
できる。The hair nourishing agent, the hair cosmetic and the skin external preparation for inhibiting sebum secretion according to the present invention include oils and fats, lower alcohols, polyhydric alcohols, and surface active agents as long as the characteristics of the present invention are not impaired. Agents, moisturizers, cell activators, fungicides,
Raw materials and additives usually used in cosmetics and skin external preparations, such as preservatives, ultraviolet absorbers, and fragrances, can be contained.
【0016】[0016]
【実施例】さらに本発明の特徴について、実施例により
詳細に説明する。EXAMPLES Further, the features of the present invention will be described in detail with reference to examples.
【0017】 [実施例1] 養毛ローション (1)エタノール 60.000(重量%) (2)酢酸トコフェロール 0.500 (3)プロピレングリコール 2.000 (4)精製水 36.498 (5)シス-ジャスモン 0.002 (6)ホップエタノール抽出物 1.000 製法:(1)〜(3)を順次(4)に添加して可溶化し、次いで
(5),(6)を添加,溶解する。(6)のホップエタノール抽
出物は、ホップ500gを細切後エタノール1.0lに
浸漬して15℃で3日間静置し、遠心分離後ろ過してろ
液を回収して調製した。Example 1 Hair Nourishing Lotion (1) Ethanol 60.000 (% by weight) (2) Tocopherol acetate 0.500 (3) Propylene glycol 2.000 (4) Purified water 36.498 (5) Cis -Jasmon 0.002 (6) Hop ethanol extract 1.000 Production method: (1) to (3) are added to (4) sequentially to solubilize, and then
Add and dissolve (5) and (6). The hop ethanol extract of (6) was prepared by slicing 500 g of hops, immersing them in 1.0 liter of ethanol, allowing them to stand at 15 ° C. for 3 days, centrifuging and filtering to collect the filtrate.
【0018】 [実施例2] ヘアーリンス (1)シリコーン油 3.000(重量%) (2)流動パラフィン 1.000 (3)セタノール 1.500 (4)ステアリルアルコール 1.000 (5)塩化ステアリルトリメチルアンモニウム 0.700 (6)グリセリン 3.000 (7)パラオキシ安息香酸メチル 0.200 (8)緑色3号 0.002 (9)精製水 89.088 (10)1.0重量%メチルジヒドロイソ 0.010 ジャスモネイトエタノール溶液 (11)セージ50容量%1,3-ブチレングリコール 0.250 抽出物 (12)タイム50容量%1,3-ブチレングリコール 0.250 抽出物 製法:(5)〜(9)の水相成分を混合,溶解して70℃に加
熱する。一方(1)〜(4)の油相成分を混合し、70℃に加
熱する。前記水相に油相を添加してホモミキサーにて乳
化し、冷却後40℃にて(10)〜(12)を添加,混合する。
(11),(12)のセージ又はタイムの1,3-ブチレングリコー
ル抽出物は、セージ又はタイム各500gをそれぞれ5
0容量%1,3-ブチレングリコール1.0l中に浸漬し、
5℃で24時間ホモジネートし、遠心分離後ろ過してろ
液を回収して調製した。Example 2 Hair rinse (1) Silicone oil 3.000 (% by weight) (2) Liquid paraffin 1.000 (3) Cetanol 1.500 (4) Stearyl alcohol 1.000 (5) Stearyl chloride Trimethylammonium 0.700 (6) Glycerin 3.000 (7) Methyl paraoxybenzoate 0.200 (8) Green No. 3 0.002 (9) Purified water 89.088 (10) 1.0% by weight methyldihydroiso 0.010 Jasmonate ethanol solution (11) Sage 50% by volume 1,3-butylene glycol 0.250 extract (12) Thyme 50% by volume 1,3-butylene glycol 0.250 extract Production method: (5) ~ The aqueous phase component of (9) is mixed and dissolved and heated to 70 ° C. On the other hand, the oil phase components (1) to (4) are mixed and heated to 70 ° C. The oil phase is added to the aqueous phase and emulsified by a homomixer. After cooling, (10) to (12) are added and mixed at 40 ° C.
The 1,3-butylene glycol extract of sage or thyme in (11) and (12) is obtained by adding 500 g of sage or thyme to 5 g each.
Immersed in 1.0 liter of 0 volume% 1,3-butylene glycol,
The mixture was homogenized at 5 ° C. for 24 hours, centrifuged, filtered, and the filtrate was recovered to prepare a filtrate.
【0019】 [実施例3] ヘアフォーム (原液処方) (1)カチオン化セルロース 3.000(重量%) (2)ポリオキシエチレン(50E.O.)硬化ヒマシ油 1.000 (3)シリコーン油 5.000 (4)ジプロピレングリコール 7.000 (5)エタノール 15.000 (6)パラオキシ安息香酸メチル 0.150 (7)精製水 68.395 (8)1.0重量%メチルジヒドロジャスモネイト 0.005 エタノール溶液 (9)ローズマリー50容量%エタノール抽出物 0.150 (10)ハッカ50容量%エタノール抽出物 0.150 (11)カミツレ30容量%グリセリン抽出物 0.150 (充填処方) 原液 90.0 液化石油ガス 10.0 製法:(3)を(2)と(4)の溶解物に添加し、ホモミキサー
で均一に乳化する。これを(1),(5)〜(11)の溶液に添加
する。充填は缶に原液を充填し、バルブ装着後液化石油
ガスを充填する。(9),(10)のローズマリー,ハッカの
エタノール抽出物、又は(11)のカミツレのグリセリン抽
出物は、これら植物各500gをそれぞれ50容量%エ
タノール又は30容量%グリセリン各1.0l中に浸漬
し、10℃で24時間ホモジネートし、遠心分離後ろ過
してろ液を回収して調製した。[Example 3] Hair foam (stock solution formulation) (1) Cationic cellulose 3.000 (% by weight) (2) Polyoxyethylene (50E.O.) hydrogenated castor oil 1.000 (3) Silicone oil 5.000 (4) Dipropylene glycol 7.000 (5) Ethanol 15,000 (6) Methyl parahydroxybenzoate 0.150 (7) Purified water 68.395 (8) 1.0% by weight methyl dihydrojasmonate 0.005 Ethanol solution (9) Rosemary 50% by volume ethanol extract 0.150 (10) Mint 50% by volume ethanol extract 0.150 (11) Chamomile 30% by volume glycerin extract 0.150 (filling formulation) Stock solution 90.0 Liquefied petroleum gas 10.0 Production method: (3) is added to the melt of (2) and (4) and homogenized with a homomixer. This is added to the solutions (1), (5) to (11). For filling, a can is filled with a stock solution, and after mounting a valve, liquefied petroleum gas is filled. The rosemary and peppermint ethanol extracts of (9) and (10) or the chamomile glycerin extract of (11) were prepared by adding 500 g of each of these plants to 1.0 liter of 50% by volume of ethanol or 1.0% of 30% by volume of glycerin, respectively. It was immersed, homogenized at 10 ° C. for 24 hours, filtered after centrifugation, and collected by filtration to prepare a filtrate.
【0020】 [実施例4] ヘアートリートメント (1)流動パラフィン 15.000(重量%) (2)ワセリン 15.000 (3)ミツロウ 2.000 (4)ポリオキシエチレン(50E.O.)硬化ヒマシ油 3.000 (5)グリセリン 5.000 (6)カルボキシビニルポリマー 0.100 (7)キサンタンガム 0.100 (8)エチレンジアミン四酢酸二ナトリウム 0.100 (9)精製水 59.395 (10)水酸化ナトリウム 0.050 (11)2.0重量%シス-ジャスモンエタノール溶液 0.003 (12)2.0重量%ジヒドロジャスモンエタノール 0.002 溶液 (13)10.0重量%オトギリソウ抽出物グリセリン 0.250 溶液 製法:(1)〜(3)の油相成分を加熱溶解し、80℃とす
る。一方(4)〜(9)の水相成分を混合,加熱溶解し、80
℃とする。これに前記油相を攪拌しながら加え、ホモジ
ナイザーにより均一に乳化する。冷却後30℃で(10)〜
(13)を添加,混合する。(13)のオトギリソウ抽出物グリ
セリン溶液は、オトギリソウ500gをエタノール1.
0l中で20℃にて5日間浸漬して得た抽出物よりエタ
ノールを蒸発乾固し、それをグリセリンにて10.0重
量%となるように溶解して調製した。Example 4 Hair Treatment (1) Liquid paraffin 15,000 (% by weight) (2) Vaseline 15.000 (3) Beeswax 2.000 (4) Polyoxyethylene (50E.O.) cured castor Oil 3.000 (5) Glycerin 5.000 (6) Carboxyvinyl polymer 0.100 (7) Xanthan gum 0.100 (8) Disodium ethylenediaminetetraacetate 0.100 (9) Purified water 59.395 (10) Water Sodium oxide 0.050 (11) 2.0 wt% cis-jasmon ethanol solution 0.003 (12) 2.0 wt% dihydrojasmon ethanol 0.002 solution (13) 10.0 wt% Hypericum extract glycerin 0. 250 solution Production method: The oil phase components (1) to (3) are dissolved by heating to 80 ° C. On the other hand, the aqueous phase components (4) to (9) were mixed and dissolved by heating.
° C. The oil phase is added thereto with stirring, and the mixture is uniformly emulsified by a homogenizer. 30 ° C after cooling (10) ~
(13) is added and mixed. The glycerin solution of the hypericum extract of (13) was prepared by adding 500 g of hypericum to ethanol 1.
Ethanol was evaporated to dryness from the extract obtained by immersing in 0 l at 20 ° C. for 5 days, and it was dissolved and dissolved in glycerin so as to be 10.0% by weight.
【0021】 [実施例5] ざ瘡治療用クリーム (1)ミツロウ 6.00(重量%) (2)セタノール 5.00 (3)還元ラノリン 8.00 (4)スクワラン 15.50 (5)グリセリル脂肪酸エステル 4.00 (6)親油型グリセリルモノステアリン酸エステル 1.50 (7)ポリオキシエチレン(20E.O.)ソルビタン 4.00 モノラウリン酸エステル (8)プロピレングルコール 5.00 (9)パラオキシ安息香酸メチル 0.10 (10)精製水 50.48 (11)2.0重量%シス-ジャスモンエタノール溶液 0.01 (12)2.0重量%メチルジヒドロイソ 0.01 ジャスモネイトエタノール溶液 (13)アルニカリン酸緩衝液抽出物 0.15 (14)セイヨウハッカリン酸緩衝液抽出物 0.25 製法:(1)〜(7)の油相成分を混合,溶解して75℃に加
熱する。一方、(8)〜(10)の水相成分を混合,溶解して
75℃に加熱する。次いで、上記水相成分に油相成分を
添加して予備乳化した後、ホモミキサーにて均一に乳化
し、冷却後40℃にて(11)〜(14)を添加する。(13),(1
4)のアルニカ又はセイヨウハッカのリン酸緩衝液抽出物
は、アルニカ又はセイヨウハッカ各750gを20mM
リン酸緩衝液(pH7.0)中で10℃にて24時間ホ
モジネートし、遠心分離後ろ過してろ液を回収して調製
した。Example 5 Acne Treatment Cream (1) Beeswax 6.00 (% by weight) (2) Cetanol 5.00 (3) Reduced Lanolin 8.00 (4) Squalane 15.50 (5) Glyceryl Fatty acid ester 4.00 (6) Lipophilic glyceryl monostearate 1.50 (7) Polyoxyethylene (20E.O.) sorbitan 4.00 Monolaurate (8) Propylene glycol 5.00 (9) Methyl paraoxybenzoate 0.10 (10) Purified water 50.48 (11) 2.0% by weight cis-jasmon ethanol solution 0.01 (12) 2.0% by weight methyl dihydroiso 0.01 Jasmonate ethanol solution (13) Arnica phosphate buffer extract 0.15 (14) Mentha phosphate buffer extract 0.25 Production method: Mix and dissolve the oil phase components of (1) to (7) and heat to 75 ° C I do. On the other hand, the aqueous phase components (8) to (10) are mixed and dissolved, and heated to 75 ° C. Next, the oil phase component is added to the water phase component and pre-emulsified, and then uniformly emulsified by a homomixer. After cooling, (11) to (14) are added at 40 ° C. (13), (1
4) The phosphate buffer extract of Arnica or peppermint is obtained by adding 750 g of Arnica or peppermint to 20 mM each.
The solution was homogenized in a phosphate buffer (pH 7.0) at 10 ° C. for 24 hours, centrifuged, filtered, and the filtrate was collected to prepare a filtrate.
【0022】 [実施例6] 抗脂漏剤 (1)ジプロピレングリコール 10.000(重量%) (2)カルボキシビニルポリマー 0.500 (3)水酸化カリウム 0.100 (4)パラオキシ安息香酸メチル 0.100 (5)精製水 88.250 (6)1.0重量%メチルジヒドロジャスモネイト 0.025 エタノール溶液 (7)1.0重量%ジヒドロジャスモンエタノール 0.025 溶液 (8)ホップ生理食塩水抽出物 1.000 製法:(5)に(2)を均一に溶解させた後、(1)に(4)を溶解
させて添加し、次いで(3)を加えて増粘させ、(6)〜(8)
を添加する。(8)のホップ抽出物は、ホップ600gを
生理食塩水1.0l中で10℃にて48時間ホモジネー
トし、遠心分離後ろ過してろ液を回収して調製した。Example 6 Antiseborrheic agent (1) Dipropylene glycol 10.000 (% by weight) (2) Carboxyvinyl polymer 0.500 (3) Potassium hydroxide 0.100 (4) Methyl paraoxybenzoate 0.100 (5) Purified water 88.250 (6) 1.0% by weight methyl dihydrojasmonate 0.025 ethanol solution (7) 1.0% by weight dihydrojasmon ethanol 0.025 solution (8) Hop physiological saline Water extract 1.000 Production method: After dissolving (2) uniformly in (5), dissolve (4) in (1) and then add (3) to increase the viscosity by adding (3). ) ~ (8)
Is added. The hop extract of (8) was prepared by homogenizing 600 g of hops in 1.0 liter of physiological saline at 10 ° C. for 48 hours, centrifuging and filtering to collect a filtrate.
【0023】上記実施例のうち、実施例1,実施例5,
実施例6について、それぞれ男性型脱毛症改善効果、ざ
瘡治療効果及びふけ,痒みの防止効果を評価した。Of the above embodiments, Embodiment 1, Embodiment 5,
For Example 6, the effect of improving male pattern baldness, the effect of treating acne, and the effect of preventing dandruff and itch were evaluated, respectively.
【0024】まず実施例1について、処方中ホップエタ
ノール抽出物をエタノールに代替したものを比較例1、
シス-ジャスモンを精製水に代替したものを比較例2、
シス-ジャスモン及びホップエタノール抽出物をセンブ
リのエタノール抽出物2.0重量%に代替し、精製水で
全量を100.0重量%としたものを比較例3として、
男性型脱毛症患者における使用試験を行った。使用試験
は男性型脱毛症患者20名を1群とし、各群に実施例及
び比較例をそれぞれブラインドにて1日2回、6カ月間
使用させ、6カ月後の発毛の程度を写真撮影により評価
して行った。評価は表1に示す判定基準に従って行い、
各評価点数を得たパネラー数にて表2に示した。First, in Example 1, the hop ethanol extract in the formulation was replaced with ethanol, and Comparative Example 1 was used.
Comparative Example 2 in which cis-jasmon was replaced with purified water,
The cis-jasmon and hop ethanol extracts were replaced with 2.0 wt% of the ethanol extract of the assembly, and the total amount was 100.0 wt% with purified water as Comparative Example 3,
A use test was conducted in male pattern baldness patients. The use test consisted of 20 male pattern bald patients as one group, each group was allowed to use the examples and comparative examples twice a day for 6 months with a blind, and photographed the degree of hair growth after 6 months. The evaluation was performed according to The evaluation was performed according to the criteria shown in Table 1.
Table 2 shows the number of panelists who obtained each evaluation score.
【表1】 [Table 1]
【0025】[0025]
【表2】 表2において示されるように、本発明の実施例1使用群
では、全患者において全体的な生毛の発生が認められて
おり、70%の患者において硬毛を認めていた。これに
対し、有効成分としてシス-ジャスモンのみを含有する
比較例1使用群では、85%の患者において全体的な生
毛発生を認めたが、硬毛の発生の見られたのは30%に
過ぎなかった。有効成分としてホップのエタノール抽出
物のみを含有する比較例2使用群でも、75%の患者に
おいて全体的な生毛発生を認めたが、硬毛の発生の見ら
れた患者はわずかに15%にとどまっていた。また有効
成分としてセンブリのエタノール抽出物を含有する比較
例3使用群では、部分的な生毛の発生は認められるもの
の、全体的な発毛の見られた患者は少なかった。また硬
毛の発生を認めた患者は見られなかった。[Table 2] As shown in Table 2, in the use group of Example 1 of the present invention, overall hair growth was observed in all patients, and 70% of the patients had ingrown hair. On the other hand, in the group using Comparative Example 1 containing only cis-jasmon as an active ingredient, 85% of the patients showed overall hair growth, but 30% of them showed hard hair. It was not too much. Even in the group using Comparative Example 2 containing only the ethanol extract of hops as an active ingredient, 75% of the patients showed overall hair growth, but only 15% of the patients showed hair growth. I was staying. Further, in the group using Comparative Example 3 containing the ethanol extract of the assembly as an active ingredient, although the occurrence of partial hair growth was observed, few patients showed overall hair growth. In addition, there was no patient that showed the occurrence of ingrown hair.
【0026】次に実施例5について、処方中アルニカ及
びセイヨウハッカの各リン酸緩衝液抽出物をリン酸緩衝
液に代替したものを比較例4、シス-ジャスモン,メチ
ルジヒドロイソジャスモネイトの各エタノール溶液をエ
タノールに代替したものを比較例5、シス-ジャスモ
ン,メチルジヒドロイソジャスモネイトの各エタノール
溶液及びアルニカ,セイヨウハッカのリン酸緩衝液抽出
物を塩酸ピリドキシン1.0重量%に代替し、精製水で
全量を100.0重量%としたものを比較例6として、
ざ瘡患者における使用試験を行った。使用試験はざ瘡患
者20名を1群とし、各群に実施例及び比較例をそれぞ
れブラインドにて1日2回、1カ月間使用させ、症状の
改善状況を観察して行った。症状の改善状況は、「改
善」,「やや改善」,「改善を認めず」の3段階で評価
し、各評価を得た患者数にて表3に示した。Next, in Example 5, Comparative Example 4 in which the phosphate buffer extract was substituted for each of the phosphate buffer extracts of Arnica and Mentha in the formulation, cis-jasmon and methyldihydroisojasmonate were used. Comparative Example 5 was obtained by replacing the ethanol solution with ethanol, and each ethanol solution of cis-jasmon and methyldihydroisojasmonate and the phosphate buffer extract of Arnica and peppermint were replaced by 1.0% by weight of pyridoxine hydrochloride. The total amount was adjusted to 100.0% by weight with purified water as Comparative Example 6,
A use test in acne patients was performed. In the use test, 20 groups of acne patients were used as a group, and each group was allowed to use the examples and the comparative examples twice a day for one month with a blind, and the improvement of symptoms was observed. The symptom improvement status was evaluated in three stages of “improvement”, “slight improvement”, and “improvement was not observed”. Table 3 shows the number of patients who obtained each evaluation.
【表3】 [Table 3]
【0027】表3において明らかなように、本発明の実
施例5使用群では20名中19名の患者に明確な改善が
認められ、改善傾向の見られなかった患者はいなかっ
た。これに対し、有効成分としてシス-ジャスモン等テ
ルペンのみを含有する比較例4使用群では、改善傾向の
認められない患者はいなかったが、明確な改善の認めら
れたのは8名にとどまっていた。有効成分としてアルニ
カ等の植物抽出物のみを含有する比較例5使用群でも改
善傾向は認められるが、明確な改善を認めたのは5名に
とどまっていた。また有効成分として塩酸ピリドキシン
を含有する比較例6使用群では、明確な改善を認めたの
は1名のみで、3名においては改善が認められていなか
った。As is clear from Table 3, 19 out of 20 patients in the group using Example 5 of the present invention showed a clear improvement, and no patients showed no improvement tendency. In contrast, in the group using Comparative Example 4 containing only a terpene such as cis-jasmon as an active ingredient, no patient showed any improvement tendency, but only 8 patients showed a clear improvement. . Even in the group using Comparative Example 5 containing only a plant extract such as arnica as an active ingredient, an improvement tendency was observed, but only 5 people showed a clear improvement. Further, in the group using Comparative Example 6 containing pyridoxine hydrochloride as an active ingredient, only one person showed a clear improvement, and no improvement was observed in three persons.
【0028】次いで実施例6について、処方中ホップの
生理食塩水抽出物を生理食塩水に代替したものを比較例
7、メチルジヒドロジャスモネイト及びジヒドロジャス
モンの各エタノール溶液をエタノールに代替したものを
比較例8、メチルジヒドロジャスモネイト,ジヒドロジ
ャスモンのエタノール溶液及びホップの生理食塩水抽出
物を塩酸ピリドキシン1.0重量%に代替し、精製水で
全量を100.0重量%としたものを比較例9として、
皮脂分泌過多の認められるふけ症患者における使用試験
を行った。使用試験はふけ症患者20名を1群とし、各
群に実施例及び比較例をそれぞれブラインドにて1日2
回、1カ月間使用させ、ふけ及び痒みの各症状の改善状
況を評価させて行った。各症状の改善状況は、「改
善」,「やや改善」,「改善を認めず」の3段階で評価
させ、各評価を得た患者数にて表4に示した。Next, in Example 6, Comparative Example 7 was obtained by replacing the physiological saline extract of hop in the formulation with physiological saline, and Example 6 was obtained by replacing each ethanol solution of methyldihydrojasmonate and dihydrojasmon with ethanol. Comparative Example 8, comparison was made between a solution of methyldihydrojasmonate, an ethanol solution of dihydrojasmon and a physiological saline extract of hops replaced with 1.0% by weight of pyridoxine hydrochloride and a total amount of 100.0% by weight with purified water. Example 9
A use test was conducted in a dandruff patient with hypersebum secretion. The use test consisted of 20 dandruff patients as a group, and each group was blinded with the examples and comparative examples 2 days a day.
It was used for one month, and the improvement status of each symptom of dandruff and itch was evaluated. The improvement status of each symptom was evaluated in three stages of “improvement”, “slight improvement”, and “improvement was not recognized”. Table 4 shows the number of patients who obtained each evaluation.
【0029】[0029]
【表4】 表4において、本発明の実施例6使用群では、全患者に
おいてふけ症状の改善傾向が認められており、19名の
患者で明確な改善が認められていた。また、痒みについ
ては全患者で明確な改善を認めていた。これに対し、有
効成分としてメチルジヒドロジャスモネイト等のテルペ
ンのみを含有する比較例7使用群では、各症状について
改善傾向を認めるものの、明確な改善を認めたのはふけ
については10名、痒みについては9名にとどまり、有
効成分としてホップの生理食塩水抽出物のみを含有する
比較例8使用群では、ふけについて9名、痒みについて
7名において明確な改善を認めたにとどまっていた。ま
た、有効成分として塩酸ピリドキシンを含有する比較例
9使用群では、明確な改善を認めたのはふけについては
4名、痒みについては3名であり、それぞれ4名及び3
名において改善を認めていなかった。[Table 4] In Table 4, in the group using Example 6 of the present invention, improvement tendency of dandruff symptoms was observed in all patients, and clear improvement was observed in 19 patients. In addition, all patients showed a clear improvement in itch. On the other hand, in the group using Comparative Example 7 containing only terpene such as methyldihydrojasmonate as an active ingredient, although there was a tendency for improvement for each symptom, 10 people for dandruff showed clear improvement, and itching was observed. In the group using Comparative Example 8 containing only a hop physiological saline extract as an active ingredient, only 9 people showed a clear improvement in dandruff and 7 people showed itching in itching. Further, in the group using Comparative Example 9 containing pyridoxine hydrochloride as an active ingredient, 4 people showed clear improvement, and 3 people showed itching.
Did not see any improvement in the names.
【0030】上記の評価結果は、本発明の実施例におい
て、本発明の構成成分であるシス-ジャスモン等のテル
ペン類とホップ等の植物抽出物とを各単独で用いる場合
に比べ、抗アンドロゲン作用の相乗的な向上により、男
性型脱毛症患者における毛髪成長促進効果、及び皮脂の
過剰分泌抑制によるざ瘡治療効果やふけ改善効果が顕著
に増強されていることを示すものである。The above evaluation results show that the examples of the present invention show that the terpenes such as cis-jasmon and the plant extract such as hops, which are the constituents of the present invention, are used in comparison with the case where the plant extracts such as hops are used alone. It is shown that the synergistic improvement of is significantly enhanced the hair growth promoting effect in male pattern baldness patients, and the acne treatment effect and dandruff improving effect by suppressing excessive secretion of sebum.
【0031】なお上記使用試験において、本発明の実施
例の使用により、皮膚又は頭皮に対する刺激性や感作性
は全く認められず、その他の副作用も認められなかっ
た。さらに、本発明の実施例1〜実施例6については、
いずれも良好な保存安定性を示した。In the above use test, no irritation or sensitization to the skin or scalp was observed at all, and no other side effects were observed by using the examples of the present invention. Further, regarding Examples 1 to 6 of the present invention,
All showed good storage stability.
【0032】[0032]
【発明の効果】以上詳述したように、本発明により、抗
アンドロゲン作用の相乗的な向上により、男性型脱毛症
の予防,改善効果が相乗的に増強された養毛剤及び毛髪
用化粧料、並びに、皮脂分泌抑制効果が相乗的に増強さ
れ、尋常性ざ瘡,脂漏等の治療,改善に非常に有効な皮
膚外用剤を得ることができた。As described above in detail, according to the present invention, a hair restorer and a hair cosmetic wherein the preventive and ameliorating effects of androgenetic alopecia are synergistically enhanced by synergistically improving the antiandrogenic action, and In addition, the effect of inhibiting sebum secretion was synergistically enhanced, and an external preparation for skin which was very effective for treating and improving acne vulgaris, seborrhea and the like was obtained.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 35/78 A61K 35/78 W ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 35/78 A61K 35/78 W
Claims (3)
ップ(Humulus lupulus L.),ローズマリー(Rosmarin
us officinalis L.),オトギリソウ(Hypericum erect
um Thunb.),ハッカ(Mentha arvensis L. var. piper
ascens Malinv.),セイヨウハッカ(Mentha piperita
L.),カミツレ(Matricaria chamomilla L.),アルニ
カ(Arnica montana L.),タイム(Thymus vulgaris
L.)の各抽出物より選択される1種又は2種以上と、化
学式(1)で表されるシス-ジャスモン(cis-jasmon
e),化学式(2)で表されるメチルジヒドロイソジャス
モネイト(methyl dihydroisojasmonate),化学式
(3)で表されるメチルジヒドロジャスモネイト(meth
yl dihydrojasmonate),及び化学式(4)で表される
ジヒドロジャスモン(dihydrojasmone)より選ばれる1
種又は2種以上を含有して成ることを特徴とする、養毛
剤。1. Sage ( Salvia officinalis L.), hop ( Humulus lupulus L.), rosemary ( Rosmarin )
us officinalis L.), Hypericum erect
um Thunb.), Mentha ( Mentha arvensis L. var. piper)
ascens Malinv.), Mentha piperita
L.), chamomile ( Matricaria chamomilla L.), arnica ( Arnica montana L.), thyme ( Thymus vulgaris )
L.) and cis-jasmon (cis-jasmon) represented by the chemical formula (1).
e), methyl dihydroisojasmonate represented by the chemical formula (2), methyl dihydroisojasmonate represented by the chemical formula (3) (meth)
yl dihydrojasmonate) and 1 selected from dihydrojasmone represented by chemical formula (4)
A hair tonic comprising at least one species or two or more species.
ップ(Humulus lupulus L.),ローズマリー(Rosmarin
us officinalis L.),オトギリソウ(Hypericum erect
um Thunb.),ハッカ(Mentha arvensis L. var. piper
ascens Malinv.),セイヨウハッカ(Mentha piperita
L.),カミツレ(Matricaria chamomilla L.),アルニ
カ(Arnica montana L.),タイム(Thymus vulgaris
L.)の各抽出物より選択される1種又は2種以上と、化
学式(1)で表されるシス-ジャスモン(cis-jasmon
e),化学式(2)で表されるメチルジヒドロイソジャス
モネイト(methyl dihydroisojasmonate),化学式
(3)で表されるメチルジヒドロジャスモネイト(meth
yl dihydrojasmonate),及び化学式(4)で表される
ジヒドロジャスモン(dihydrojasmone)より選ばれる1
種又は2種以上を含有して成ることを特徴とする、毛髪
用化粧料。2. Sage ( Salvia officinalis L.), hop ( Humulus lupulus L.), rosemary ( Rosmarin )
us officinalis L.), Hypericum erect
um Thunb.), Mentha ( Mentha arvensis L. var. piper)
ascens Malinv.), Mentha piperita
L.), chamomile ( Matricaria chamomilla L.), arnica ( Arnica montana L.), thyme ( Thymus vulgaris )
L.) and cis-jasmon (cis-jasmon) represented by the chemical formula (1).
e), methyl dihydroisojasmonate represented by the chemical formula (2), methyl dihydroisojasmonate represented by the chemical formula (3) (meth)
yl dihydrojasmonate) and 1 selected from dihydrojasmone represented by chemical formula (4)
A hair cosmetic, characterized by comprising a seed or two or more kinds.
ップ(Humulus lupulus L.),ローズマリー(Rosmarin
us officinalis L.),オトギリソウ(Hypericum erect
um Thunb.),ハッカ(Mentha arvensis L. var. piper
ascens Malinv.),セイヨウハッカ(Mentha piperita
L.),カミツレ(Matricaria chamomil la L.),アルニ
カ(Arnica montana L.),タイム(Thymus vulgaris
L.)の各抽出物より選択される1種又は2種以上と、化
学式(1)で表されるシス-ジャスモン(cis-jasmon
e),化学式(2)で表されるメチルジヒドロイソジャス
モネイト(methyl dihydroisojasmonate),化学式
(3)で表されるメチルジヒドロジャスモネイト(meth
yl dihydrojasmonate),及び化学式(4)で表される
ジヒドロジャスモン(dihydrojasmone)より選ばれる1
種又は2種以上を含有して成ることを特徴とする、皮脂
分泌抑制用皮膚外用剤。 【化1】 【化2】 【化3】 【化4】 3. Sage ( Salvia officinalis L.), hop ( Humulus lupulus L.), rosemary ( Rosmarin )
us officinalis L.), Hypericum erect
um Thunb.), Mentha ( Mentha arvensis L. var. piper)
ascens Malinv.), Mentha piperita
L.), chamomile ( Matricaria chamomil la L.), arnica ( Arnica montana L.), thyme ( Thymus vulgaris )
L.) and cis-jasmon (cis-jasmon) represented by the chemical formula (1).
e), methyl dihydroisojasmonate represented by the chemical formula (2), methyl dihydroisojasmonate represented by the chemical formula (3) (meth)
yl dihydrojasmonate) and 1 selected from dihydrojasmone represented by chemical formula (4)
A skin external preparation for inhibiting sebum secretion, comprising a seed or two or more kinds. Embedded image Embedded image Embedded image Embedded image
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9267818A JPH1179948A (en) | 1997-09-12 | 1997-09-12 | Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9267818A JPH1179948A (en) | 1997-09-12 | 1997-09-12 | Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH1179948A true JPH1179948A (en) | 1999-03-23 |
Family
ID=17450042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9267818A Pending JPH1179948A (en) | 1997-09-12 | 1997-09-12 | Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH1179948A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805158A1 (en) * | 2000-02-18 | 2001-08-24 | L M D | COSMETIC OR MEDICINAL COMPOSITION CONTAINING A SESQUITERPENIC LACTONE OR THE LIKE FOR TREATING DISORDERS RELATED TO PILAR GROWTH, AND PROCESS FOR PREPARING THE SAME. |
| WO2002076410A3 (en) * | 2001-03-23 | 2003-09-25 | Beiersdorf Ag | Cosmetic and dermatological preparations comprising a content of a hop extract or hop-malt extract |
| JP2004505900A (en) * | 2000-08-03 | 2004-02-26 | ダウ ファーマシューティカル サイエンシーズ | Topical gel delivery system |
| FR2850571A1 (en) * | 2003-01-31 | 2004-08-06 | Oreal | USE OF A JASMONIC ACID (DIHYDRO) DERIVATIVE FOR THE TREATMENT OF DRY SKIN |
| JP2007169245A (en) * | 2005-12-26 | 2007-07-05 | Soda Aromatic Co Ltd | Arachidonic acid metabolism inhibitor |
| US8461206B2 (en) | 2003-01-31 | 2013-06-11 | L'oreal | Use of at least one (dihydro)jasmonic acid derivative for treating dry skin |
-
1997
- 1997-09-12 JP JP9267818A patent/JPH1179948A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805158A1 (en) * | 2000-02-18 | 2001-08-24 | L M D | COSMETIC OR MEDICINAL COMPOSITION CONTAINING A SESQUITERPENIC LACTONE OR THE LIKE FOR TREATING DISORDERS RELATED TO PILAR GROWTH, AND PROCESS FOR PREPARING THE SAME. |
| WO2001060326A3 (en) * | 2000-02-18 | 2002-06-20 | L M D | Cosmetic or pharmaceutical composition containing sesquiterpene lactone |
| JP2004505900A (en) * | 2000-08-03 | 2004-02-26 | ダウ ファーマシューティカル サイエンシーズ | Topical gel delivery system |
| WO2002076410A3 (en) * | 2001-03-23 | 2003-09-25 | Beiersdorf Ag | Cosmetic and dermatological preparations comprising a content of a hop extract or hop-malt extract |
| FR2850571A1 (en) * | 2003-01-31 | 2004-08-06 | Oreal | USE OF A JASMONIC ACID (DIHYDRO) DERIVATIVE FOR THE TREATMENT OF DRY SKIN |
| EP1442737A3 (en) * | 2003-01-31 | 2004-08-11 | L'oreal | Use of a (dihydro)jasmonic acid derivative for dry skin treatment |
| US8461206B2 (en) | 2003-01-31 | 2013-06-11 | L'oreal | Use of at least one (dihydro)jasmonic acid derivative for treating dry skin |
| JP2007169245A (en) * | 2005-12-26 | 2007-07-05 | Soda Aromatic Co Ltd | Arachidonic acid metabolism inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3568325B2 (en) | Anti-androgen agent, hair restorer, and hair cosmetic | |
| JP2001354579A (en) | Anti-inflammatory cosmetics | |
| JPH09194334A (en) | Hair nourishing agent | |
| JP4033981B2 (en) | Testosterone 5α-reductase inhibitor | |
| JP5047527B2 (en) | Topical skin preparation | |
| JPH1179948A (en) | Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion | |
| JP3809003B2 (en) | Whitening agent | |
| JPH05139951A (en) | Face powder | |
| JPH06271452A (en) | Skin cosmetic containing extract of plant of cactuses | |
| JP3505200B2 (en) | Hair restorer | |
| JP2891727B2 (en) | Hair restoration | |
| CN102724959A (en) | Composition for preventing hair loss and stimulating hair growth | |
| JP2003137742A (en) | Hair growing agent comprising evolvulus plant extract and other galenical extract | |
| JP5059598B2 (en) | Hair growth promoting composition | |
| JP2002154919A (en) | Elongation inhibitor of dendrite of melanocyte and cosmetic comprising the same | |
| JP3647295B2 (en) | Lipid peroxide production inhibitor and composition containing the same | |
| JP2002154920A (en) | Elongation inhibitor of dendrite of melanocyte and cosmetic comprising the same | |
| JP2855274B2 (en) | Hair restoration | |
| JP3647296B2 (en) | Inhibition of tyrosinase activity and compositions containing the same | |
| JP7402478B2 (en) | Nerve growth factor expression inhibitor and semaphorin 3A expression promoter | |
| JPH09157151A (en) | Melanin generation inhibitor and whitening agent | |
| JP3799340B2 (en) | Hydroxytyrosol, application to topical skin preparation | |
| JP2811479B2 (en) | Hair restoration | |
| JP3792053B2 (en) | Lipid peroxide production inhibitor and composition containing the same | |
| JP2001131027A (en) | Hair restorer and hair wash |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040224 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040628 |